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Abstract 
Recently it has been demonstrated that Fetuin-A, an anti-inflammatory protein synthesized by the 
liver, is produced also in bone by an FGF23-regulated pathway. FGF23 has been also demonstrated 
to induce inflammatory cytokine production in the liver. This study aimed to explore if FGF23 plays 
a role in the Fetuin-A production in the liver cells too and the possible relationships with FGF23 
pro-inflammatory effects. 
FGF23 and Fetuin-A were studied in liver, kidney and in plasma with immunochemistry, 
immunoprecipitation, western blot, chromatin immunoprecipitation, duolink, ELISA, qrtPCR 
methodology.  
FGF23 is produced, but not secreted by the liver cells. In hepatocytes and circulation, FGF23 was 
present only strictly linked to Fetuin-A, while Fetuin-A was found also in unbounded form. No link 
was observed in the kidney. FGF23 up to 600 pg/ml stimulates, while, at higher concentrations, 
reduces Fetuin-A expression. Notably, overall the range of concentrations, FGF23 stimulates 
Fetuin-A promoter, TNFα and IL6 expression. In the nucleus, FGF23 seems to act as a direct 
transcription factor of Fetuin-A promoter. 
These results suggest that FGF23 played a direct regulatory role in Fetuin-A expression in liver cells 
with a biphasic effect: Fetuin-A progressively increases when FGF23 increases up to 400-600 pg/mL, 
and declines at higher FGF23 concentrations. These results lead us to hypothesize: a) a possible 
epigenetic post-transcriptional regulation; b) a possible counter-regulatory effect of FGF23 induced 
inflammatory cytokines (TNFα/ NF-κB mechanism). This study could add an additional key for the 
interpretation of the possible mechanisms linking FGF23, Fetuin-A and inflammation in CKD 
patients and suggests a role for FGF23 as transcription factor. 
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Introduction 
Bone, kidney and intestine are the organs 
involved in maintaining the balance of phosphate and 
calcium both in normal subjects and in chronic kidney 









FGF23, an osteocyte (OS) derived hormone, 
plays a key role in this network [1-5]. It has been 
widely reported that FGF23 levels can increase from 
the beginning of kidney diseases, achieving very high 
blood concentrations at the advanced CKD stages. 
These high FGF23 levels have been claimed to be 
involved not only in the mineral metabolism 
derangements but also to possibly affect the 
progression of cardiovascular disease (CVD) and 
CKD itself, adding negative effects to the poor clinical 
outcomes of CKD [6-8]. 
Fetuin-A is a multifunctional protein mainly 
produced by the liver [9] that plays different roles 
such as the prevention of vascular calcium deposition 
and the anti-inflammatory function [10-16].  
These two properties are to a certain extent 
inter-related to each other, since it is acknowledged 
that Fetuin-A is either up- or down-regulated by 
different inflammatory cytokines, with a potential 
negative effect on the CV system in the case of its 
down-regulation [17-20]. 
We recently found that FGF23 strictly controls 
Fetuin-A production in the bone and that the 
handling of FGF23 activity (addition of recombinant 
FGF23, gene deletion and overexpression), with the 
simultaneous modulation of FGF receptors, clearly 
showed a potential paracrine and endocrine role of 
FGF23 on Fetuin-A expression and production [21, 
22]. A recent paper demonstrated an ectopic FGF23 
overexpression in the hepatocytes in two patients 
with end-stage liver disease [23], another article 
described the presence of FGF23 in the hepatocytes of 
CKD mice, where it induced the release of 
inflammatory factors [24], this being the case we 
might then hypothesize a potential physiological or 
pathological role of FGF23 in the liver [25]. 
The first aim of the present study was to 
investigate if FGF23 might be involved in Fetuin-A 
production also in the liver and, if this was the case, 
through which biochemical mechanism. The second 
aim was to explore the possible inter-relationship 
between the FGF23-dependent processes of Fetuin-A 
and inflammatory cytokine release. Among the 
inflammatory cytokines, we focused on TNFα, for its 
recognized pathogenic role in the acute systemic 
inflammatory process [26-29].  
Furthermore, since our previous study showed 
that FGF23 and Fetuin-A are bound to each other in 
both the cytoplasm and nucleus of bone cells, and 
most of all in the bone matrix and possibly in the 
circulation, we looked for a possible link between 
these two proteins also in the plasma and in the 
kidney, as one of the principal targets of FGF23 action 
[30-32]. 
Materials and Methods 
Tissues, cell culture and plasma  
Liver and kidney Tissue Specimens  
Frozen kidney tissues were extracted from the 
non-injured part of the human nephrectomy. Human 
tissues and plasma (see below) were processed after 
the patients informed consent was obtained and 
approved by Director of Nephrology-Urology and 
Kidney Transplantation Unit (NUTRAR) of 
Fondazione IRCCS Ca' Granda Ospedale Maggiore 
Policlinico. Protocol n°: M.04. NUTRAR. CONS. rev.0. 
of 30/03/2015.  
Frozen liver tissues of 6 weeks old male BALB/c 
mice (IRCCS San Martino-IST Genoa, IT) were used. 
All efforts were made to minimize animal suffering 
and to use only the minimum number of animals 
necessary. All animals were housed on a 12-h 
light/dark cycle, allowed free access to food and 
water and killed by decapitation after anesthesia 
induced by intraperitoneal injection of 370mg/Kg of 
Chloral hydrate. 
All procedures involving animals were 
performed in accordance with the European 
legislation (European Communities Council Directive 
of 24 November 1986, 86/609/ EEC) and complied 
with the European Communities Parliament and 
Council Directive of 22 September 2010 (2010/63/EU) 
and with the Italian (D.L.vo n. 26/2014), and were 
reviewed and approved by the licensing and Ethical 
Committee of the IRCCS-AOU San Martino-IST 
National Cancer Research Institute, Genoa (Italy) 
protocol n°371, and by the Italian Ministry of Health. 
Hepatocytes and HepG2 
Primary human hepatocytes (Lonza, Basel, 
Switzerland) were thawed and plated on collagen 
type I Solution (StemCell Technologies, Vancouver, 
BC, Canada) pre-coated flasks in complete Plating 
Medium (Lonza). Hepatocytes were then cultured in 
Maintenance Medium (Lonza) following the 
manufacturer’s instructions. Human hepatocellular 
carcinoma cell line HepG2 (LGC Standards, Sesto San 
Giovanni, Italy) was cultured onto collagen-coated 
flasks in IMDM+Glutamax® supplemented with 20% 
FBS, 1% non-essential amino acids and 1% 
penicillin/streptomycin (all from Gibco/Life 
Technologies, Milan, Italy). Cells were maintained at 
37°C in a humidified 5% CO2 incubator. 
Podocytes 
Conditionally immortalized podocytes SV1 (SV1) 
from transgenic H-2Kb-tsA58 mice (CLS, Eppelheim 
Germany) were plated on collagen type IV 
(Sigma-Aldrich, Milan, Italy) at 33°C with DMEM: F12 





medium supplemented with 10% FCS, 1% 
penicillin/streptomycin, 2mM L-glutamine and 
20U/ml recombinant mouse γ interferon (all from 
Sigma-Aldrich).  Subsequently podocytes were 
thermo-shifted to 37°C for differentiation for 7 days 
and grown with the complete medium, without 
γ-interferon, in pre-coated flasks.  
Osteocytes 
The MC3T3-E1 cell line was obtained from 
ATCC (LGC Standards S.r.l) and cultured in 
alpha-MEM (Invitrogen, Milan, Italy), supplemented 
with 10% FBS (Sigma-Aldrich) and 1% 
penicillin/streptomycin (Sigma-Aldrich) in 75-cm2 
flasks at a density of 400 000 cells/cm2. When cells 
reached 80% confluence, 50µg/ml ascorbic acid and 
3mM glycerol 2-phosphate disodium salt hydrate 
AA/GP (Sigma-Aldrich) were added and the medium 
was changed every other day. After 5 days of 
incubation with AA/GP, the cells were re-plated at a 
density of 7 000 cells/cm2 and cultured with basal 
medium plus AA/GP and 10uM All Trans Retinoic 
Acid (Sigma-Aldrich) to obtain OS [33]. OS were 
studied at the 4th day of treatment.  
Plasma  
Cytospin slides were obtained by centrifugation 
of 200μl of 5 patients (3 with elevated and 2 with low 
FGF23 concentrations) (1:1 in PBS) on microscope 
glass slides at 300 rpm for 2min. In parallel, 50μl of 
undiluted plasma drawn from the same 5 above 
patients were smeared on slides for further analyzes 
(see below).  
Immunohistochemistry and 
immunocytochemistry  
Liver and kidney tissue 
Cold acetone fixed human kidney tissue sections 
were incubated with anti-FGF23 and anti-Alpha-2- 
HS-glycoprotein antibodies. 
Mouse liver tissue sections were incubated with 
anti-FGF23 [M251] and, after M.O.M kit blocking 
(Vector Labotatories, USA), with anti-Alpha-2-HS- 
glycoprotein for 1h RT followed by relative secondary 
antibodies for 1h RT. Specificity of Ab labelling was 
demonstrated by the lack of staining after substituting 
the primary antibody with the isotype ctrl. Images 
were acquired by Zeiss AxioObserver microscope 
equipped with high resolution digital videocamera 
(AxioCam, Zeiss) and Apotome system for structured 
illumination and recorded by AxioVision software 
4.8. All antibodies information in Table S1.  
Hepatocytes and HepG2 
Hepatocytes and HepG2 cultured on cover slips 
for 24h were fixed in cold acetone for 5 min and 
permeabilized with 0.3 % of Triton X-100 (Sigma- 
Aldrich) in PBS for 30min RT and then incubated with 
1 % of bovine serum blocking solution for 1h RT. 
Immunocytochemistry was performed with anti- 
FGF23, anti-Alpha-2-HS-glycoprotein, anti-clathrin 
and anti-Human serum albumin o/n at 4°C followed 
by relative secondary antibodies for 1h RT. Specificity 
of Ab labelling and neg ctrl was performed as 
described above. All antibodies information in Table 
S1.  
Plasma of CKD patients 
Cytospin of plasma and plasma smear were 
fixed in cold acetone for 3 min and incubated in 1 % of 
bovine serum blocking solution in PBS for 30min RT. 
Immunochemistry was performed as described above 
following human tissues procedure.  
Immunoprecipitation (IP) and western blot 
(WB) 
1mg of HepG2 lysate and 700µg of plasma of five 
patients (3 with high and 2 with low FGF23 
concentrations) were IP-ed with anti-FGF23 [M-251] 
(5ug antibody/1mg protein) using the standard 
protocol (Thermofisher, USA). Positive control was 
performed using the 10% protein lysate of HepG2 and 
the plasma at high and low FGF23 level to indicate the 
specific band, negative control was performed on 
samples IP-ed with normal rabbit IgG to evaluate the 
IP efficiency. 
IP of HepG2 and plasma were then separated on 
a SDS-PAGE and transferred by electroblotting on a 
PVDF membrane (ImmunBlot PVDF membrane, 
Bio-Rad). After blocking solution (BM Chemilumi-
nescence WBting Kit Roche, USA), each membrane 
was incubated with the primary antibodies 
anti-FGF23 and anti-Alpha-2-HS-glycoprotein diluted 
in TBS followed by the HRP-conjugated secondary 
antibodies in blocking solution. Positive reaction 
products were identified by chemiluminescence (BM 
Chemiluminescence WBting Kit). Loading controls for 
HepG2 were conducted with anti-cofilin antibody. 
To confirm that IP was successful, we repeated 
the same WB also on the component non FGF23/IP 
with FGF23 antibody. The same WB was performed 
with mouse anti-Alpha-2-HS-glycoprotein on the 
same component evaluated to see if Fetuin-A could 
circulate without FGF23 binding.  
To avoid the interference of background signals 
caused by heavy and light chains from IgGs, we 
repeated the experiment also with Clean-Blot IP 
detection reagent Kit (following the manufacter’s 
instructions of Thermofisher, USA) and no difference 
was observed. In this last method we blocked the 





membrane with StartingBlock T20 (TBS), we used the 
same primary antibodies concentration diluted in TBS 
blocking buffer and for the secondary antibody we 
used a dilution of 1:200 of clean-blot IP detection 
reagent HRP in TBS. Images were digitally acquired 
by Chemidoc XRS instrument (Bio-Rad) and analyzed 
by Quantity One software (Bio-Rad). All antibodies 
information in Table S1. 
FGF23 addition 
For evaluation of FGF23 effect on FGF23, 
Fetuin-A, TNFα, IL6 and Fetuin-A promoter 
expression, HepG2 were stimulated with different 
concentrations of human recombinant FGF23 
(100-12500pg/mL) (Immunological Sciences, Roma, 
Italy) for 24h. 
FGF23 overexpression 
20000 cells/cm2 of HepG2 were transfected with 
10nM human ORFclone cDNA clone FGF23 
(Myc-DDK tagged) (OriGene Technologies Inc.MD, 
USA) using Lipofectamine2000 (Invitrogen) as 
transfection agent for 24h. As control, only 
Lipofectamine2000 was applied. 
mRNA extraction and qRT-PCR 
Total RNA of primary Hepatocytes, HepG2, OS 
and podocytes were extracted by Trizol (Invitrogen), 
precipitated by chloroform and isopropanol, washed 
in ethanol 75%, treated with DNase (Invitrogen) and 
then suspended in nuclease free-water. cDNA was 
prepared from 1μg RNA using the iScript Select 
cDNA Synthesis Kit and oligo(dt)20 primers (Bio-Rad, 
Segrate, Milan, Italy). After assessment of primer 
specificity, mRNA extracted was used to evaluate 
human FGF23, AHSG, TNFα, IL6, AHSG promoter 
and mouse FGF23. To verify the absence of genomic 
DNA in the samples, qRT-PCR was performed also on 
the original RNA (minus-reverse transcriptase). Data 
were normalized against the expression of human 
RPL4 or mouse RPL13. Real Time RT-PCR were run 
with iQ Sybr Green Supermix (Bio-Rad) on a MyIQ 
instrument (Bio-Rad), and data were analyzed by the 
IQ5 Bio-Rad Software. All primers information in 
Table S2.  
Enzyme-linked immunosorbent (ELISA) tests 
FGF23 levels in the cultured cell supernatants 
were evaluated by ELISA Kit (KAINOS laboratories, 
Japan). The minimal detectable concentration is 
3pg/mL. The FGF23 levels of both hepatocytes and 
HepG2 supernatant were compared to OS (positive 
ctrl) and to both cells culture media (negative ctrl). 
Replicate background measurements were subtracted 
to all 450nm measures. To normalize Janus Green 
Whole-Cell Stain (Thermofisher) was added for 5min. 
Careful washing was followed by addition of Elution 
Buffer and absorbance was read at 630nm. The 
resulting A450 values were then normalized to the 
A630 values to account for differences in numbers of 
cells. Plasma level of FGF23 and Fetuin-A were 
measured by Human FGF23 (Intact) (Immunotopics, 
USA) and Human Fetuin-A (BioVendor, Heidelberg 
Germany) ELISA kits. The lowest concentration of 
Human FGF23 measurable is 1.5pg/mL. Limit of 
detection of Human Fetuin-A is 3.5µg/mL.  
Protein interaction 
To detected Fetuin-A/FGF23 interactions in the 
HepG2 and in the plasma, Duolink (Sigma-Aldrich) in 
situ experiment was performed following the 
manufacturer’s instructions. Cells were fixed in PFA 
for 10min, blocked for 30min (Sigma-Aldrich) and 
stained with anti-FGF23 and anti-Alpha-2-HS- 
glycoprotein o/n at 4°C. A second incubation with 
PLUS/MINUS PLA probe was performed and after 
ligation and amplification (both from Sigma) we 
visualized the interaction by immunofluorescence. As 
negative ctrl, we chose to omit one of the two 
antibodies alternatively. 
Chromatine immunoprecipitation (CHIP) and 
semi quantitative PCR 
CHIP of 106 cells of HepG2 were performed 
using the standard protocol (Thermofisher, USA) with 
antibodies rabbit anti-FGF23, anti-normal rabbit IgG 
as negative control and anti-RNA polymerase II as 
positive control (Thermofisher). PCR were performed 
on 10% on DNA as INPUT, on CHIP with FGF23 and 
on negative and positive ctrl.  
The primers tested for Fetuin-A promoter are 
designed from a sequence declared by IDT as 
promoter sequence of Fetuin-A and verified by Blast, 
on the contrary for the sample immunoprecipitated 
with RNA polymerase II, the primers came from 
GAPDH provided by Thermoscientific KIT. 
Amplification conditions were PCR buffer with 
2.5mM MgCl2, 200nM each primer and fast Start Taq 
in the presence of 200nM dNTPs (Roche). Samples 
were amplified step 1: 6’ at 95°C, step 2: 35’’ at 95°C, 
step 3: 35’’at 57,5°C-60°C, step 4: 50’’at 72°C, step 5: 
from step 2 (x12), step 6: 35’’at 95°C, step 7: 35’’ at 
57°C, step 8: 50’’ at72°C, step 9: from step 6 (x23), step 
10: 9’at 72°C, step 11: 4°C. The presence of PCR 
products (146bp) Fetuin-A promoter were resolved 
with loading dye on 2% agarose gels containing 3µl 
ethidium bromide in 0.5X Tris Borate EDTA (TBE) 
buffer alongside a low molecular weight DNA ladder 
(Invitrogen) and photographed under UV light using 
a GelDoc system (Bio-Rad, Segrate, Milan, Italy). 






Experiments were conducted on at least 3 
replicates per each condition. Data were expressed as 
mean ± standard deviation, Student's t-test was 
applied to determine significance (p<0.05). For 
qRT-PCR, relative RNA abundance was determined 
using the comparative Ct method. The fold-change 
was calculated by the software [34]. 
Results 
Fetuin-A and FGF23 expression in the liver 
FGF23 and Fetuin-A expression in mouse liver tissues 
Fetuin-A (Fig 1A, D) and FGF23 (Fig 1B, E) were 
highly represented in mouse liver tissue. However, 
while the FGF23 appeared always colocalized with 
Fetuin-A, the immunopositivity for Fetuin-A was also 
present separately (Fig 1C, F, I). The Neg Ctrl was 
performed to verify a possible non-specific signal. 
While no positivity was present around the bile duct 
and the hepatic artery (Fig 1G), a faint positivity for 
Fetuin-A was present on the branch of portal vein (Fig 
1H). Dapi staining has been deliberately shown to 
demonstrate the tissue presence. 
 Fetuin-A, FGF23 and Clathrin expression in the 
primary Human Hepatocytes and HepG2  
Preliminarily, albumin expression was tested in 
cultured hepatocytes to evaluate their functional 
activity (data not shown). A high expression of 
Fetuin-A (Fig 2A, D) and FGF23 (Fig 2B, E) was 
detected in both primary hepatocytes and HepG2 
cells, in basal conditions, with a close co-localization 
at the IS. It was also evident that Fetuin- A was in part 
bound and in part unbound to FGF23 (Fig 2C, F). The 
negative Ctrl was performed to verify a possible 
non-specific signal (Blue Fig 2C, F). Since a punctuate 
staining of Fetuin-A in HepG2 may suggest an 
endosome localization of Fetuin-A/FGF23 complexes, 
we decided to perform a Fetuin-A (Fig 3A), FGF23 
(Fig 3B), and Clathrin (Fig 3C), experiment of 
co-localization. A good co-localization of Fetuin-A, 
FGF23 and Clathrin was evident visualized Fig 3D. 
Fetuin-A and FGF23 gene expression in human 
hepatocytes and HepG2; FGF23 expression in primary 
hepatocytes compared to osteocytes and podocytes  
To compare the expression of Fetuin-A and 
FGF23 in hepatocytes and HepG2 we performed a 
Quantitative Real Time RT-PCR (qRT PCR). While 
Fetuin-A was expressed at a higher extent in primary 
hepatocytes compared to HepG2, FGF23 expression 
was not significantly different in the two cell lines (Fig 
4A). Then we explored FGF23 production in 
hepatocytes in comparison with osteocytes 
(well-known FGF23 secreting cells) and podocytes 
(negative control). Primary hepatocytes expressed a 
significant amount of FGF23 compared to podocytes 
(negative Ctrl), but far less than OS (positive Ctrl) (Fig 
4B). 
FGF23 and Fetuin-A protein 
expression and link in HepG2 
To investigate more in 
depth the interaction between 
Fetuin-A and FGF23 in the liver 
cells, we performed a Fetuin-A 
and FGF23 WB analysis in 
HepG2 (Fig 5) and primary 
hepatocytes (data not shown) 
immunoprecipitated with 
FGF23. We found, as expected, 
a strong positivity for FGF23 
mature fragment (48kD) (Fig 
5AI) in the FGF23 WB but not in 
the non-FGF23/IP fraction (Fig 
5AII). A clear band of Fetuin-A 
(39kD) was evident in the 
FGF23/IP fraction (Fig 5AIII) 
and to a by far lesser extent in 
the non-FGF23/IP fraction (Fig 
5AIV). The paucity of this last 
free component could be due to 
the dilution requested by the 
manufacturer’s instructions. 
 
Figure 1. IS (immunostaining) of Fetuin-A (A, D), FGF23 (B, E) and MERGE (C, F) visualized respectively by Fitc 
and rhodamine in mouse liver tissue; In panel I, a magnification of the part indicated by the rectangle in panel F is 
shown. The Neg Ctrl (G, H) exhibits only nuclear DAPI (4',6-diamidino-2-phenylindole) staining, attesting the cell 
presence. The arrow shows a faint parietal positivity for Fetuin-A, in a portal vein branch (H), but not in the bile 
duct and hepatic artery branch (G). Scale bars A, B, C: 100µm; D, E, F, G, H: 50µm. 





Positive control confirmed the correctness of the 
bands, negative control avoided the presence of false 
positivity (Fig S1), a very faint signal for IgG was 
present. The interaction between Fetuin-A and FGF23 
was confirmed by the Duolink assay which was 
highly positive in the HepG2 cells (Fig 5B) and 
completely negative in the Ctrl (Fig 5C).  
FGF23 liver release  
The release of intact FGF23 was substantially 
null in hepatocytes cell cultures and comparable to 
media negative Ctrl with no significant difference 
between primary hepatocytes and HepG2, at variance 
with the positive control of OS cultures (Fig 6). 
Fetuin-A and FGF23 interaction in the liver 
cells 
FGF23, Fetuin-A, TNFα and IL6 expression after 
FGF23 recombinant addition and overexpression on 
HepG2 
The addition of increasing doses (from 100 up to 
12500 pg/mL) of recombinant FGF23 induced a 
progressive increase in FGF23 mRNA in HepG2 cells 
(Fig 7A). The same doses of FGF23 induced a biphasic 
effect on Fetuin-A mRNA, with a significant increase 
for doses up to 600 pg/mL, followed by a progressive 
reduction at higher doses (Fig 7B).  
 
 
Figure 2. Fetuin-A (A, D), FGF23 (B, E) and merge (C, F) expression visualized respectively by Fitc and rhodamine IS in primary hepatocytes and in HepG2. Arrows 
show Fetuin-A immunopositivity not co-localized. The negative Ctrl exhibits only nuclear DAPI staining (C, F in blue). Scale Bars: 50μm. 
 
 
Figure 3. Fetuin-A (A), FGF23 (B), Clathrin (C) and MERGE expression (D) visualized respectively by Fitc, CY5 and rhodamine IS in HepG2. Scale Bars: 50μm. 






Figure 4. mRNA expression of Fetuin-A and FGF23 in primary hepatocytes 
and HepG2 (A). qRT PCR of FGF23 in primary hepatocytes compared to 
podocytes (negative control) and OS (Positive Ctrl) (B). Asterisks indicate 
significant differences: ***=p<0.001 by Student’s t-test. n=3/group. 
 
Then we analysed the effects of FGF23 
overexpression on Fetuin-A expression in HepG2 
transfected with mouse cDNA clone FGF23. After we 
verified the expected increase of FGF23 mRNA (Ctrl) 
(Fig 7D), we found that FGF23 overexpression was 
followed by a reduction of Fetuin-A mRNA (Fig 7E).  
We explored also the effects of FGF23 addition 
and overexpression on TNFα, a classic inflammatory 
cytokine. 24h after either FGF23 addition or 
overexpression, TNFα showed a progressive increase 
with a figure that resembled very closely that 
observed for the FGF23 behavior (Fig 7C, F). To 
support the hypothesis of inflammatory system 
implication, we checked for IL6 expression at low and 
high concentrations of added and overexpressed 
FGF23: in all these cases, IL6 upregulations was 
evident (Fig S2). 
Fetuin-A Promoter activation and biochemical 
mechanism 
 In order to investigate a possible nuclear 
FGF23-Fetuin-A promoter interaction, we performed 
a CHIP with FGF23 on HepG2 followed by a 
polymerase chain reaction (PCR) amplification for the 
identification of the Fetuin-A promoter we chose to 
investigate. The positivity for the chosen band (146 
bp) indicated that the fragment immunoprecipitated 
by FGF23 corresponds to the Fetuin-A promoter (Fig 
8A). A false positivity was excluded by the IgG 
control, while the correctness of the PCR was 
confirmed by the positive control and the input. Then, 
we decided to investigate the behaviour of Fetuin-A 
promoter after scalar additions of FGF23 and after 
FGF23 overexpression. In all these conditions the 
Fetuin-A promoter activation occurred (Fig 8B). 
FGF23 and Fetuin-A protein expression and 
interaction in the circulation 
Since the strong expression of Fetuin-A (Fig 9A) 
and FGF23 (Fig 9B) in the liver tissue was 
characterized by a strict co-localization (Fig 9C) not 
only in the liver cells but also in the interstice of the 
portal vein, we looked for a possible co-localization of 
these two proteins also in the circulation. In fact, a 
strong positive interaction of 
FGF23 and Fetuin-A was 
observed by Duolink in situ 
experiments in the plasma of 
CKD patients obtained by 
cytospin (Fig 9D). To avoid the 
possibility of false positive 
results in the duolink assay due 
to the cytospin centrifugation 
method, the co-localization of 
FGF23 and Fetuin-A was also 
assessed with IS in the plasma of 
CKD patients prepared by both 
cytospin and smear methods. 
Both methods confirmed either a 
strong co- 
localization of the two proteins 
and the presence of bound and 
unbound Fetuin-A (Fig 10). To 
further confirm this interaction, 
 
Figure 5. WB of FGF23 on HepG2 FGF23/IP (AI) and on the portion non-FGF23/IP (negative Ctrl) with FGF23 
(AII). WB of Fetuin-A on FGF23/IP (AIII) and on the aliquot non- FGF23/IP (AIV). Cofilin (bottom of the gel) acted 
as loading control (LC). Cell localization of Fetuin-A and FGF23 interactions detected by Duolink in situ 
experiment in HepG2 (B) and negative Ctrl (C) Scale bars: A, B: 50µm.  





we performed FGF23 and Fetuin-A WB in the plasma 
of 3 FGF23 plasma samples, a strong visible band of 
FGF23 at 48kD (Fig 9E P1I, P2III, P3V, FGF23 P4, P5) 
and of Fetuin-A at 39kD (Fig 9E P1VII, P2IX, P3XI, 
Fetuin-A P4, P5) were detected in the FGF23/IP 
samples. In the non-FGF23/IP aliquot we did not find 
any FGF23 band (Fig 9E P1II, P2IV, P3VI), whereas a 
clear band of Fetuin-A was evident also in this aliquot 
(Fig 9E P1VIII, P2X, P3XII). The correctness of the 
explored bands is confirmed by the negative and 
positive controls, as shown in Fig S1. 
The quantitative measurement of FGF23 in 
plasma of 5 CKD patients in pg/ML was: (P1: 841.2, 
P2:603.4, P3:547 P4:26.9, P5: 18.1) and the dosage of 
Fetuin-A in G/L was (P1: 0.372, P2:0.342, P3:0.335, 
P4:0.266, P5: 0.222). 
 
 
Figure 6. Cells Cultured medium harvested from primary hepatocytes, 
HepG2, and OS for measurement of intact FGF23 release, assessed by ELISA. 
(n=3/group; mean ±SD; data were normalized by Janus Green Nuclear marker; 
***=p<0.001 OS vs all the other groups). 
 
 
Figure 7. Changes in FGF23, Fetuin-A and TNFα mRNA expression after 24h 
from the addition of scalar FGF23 dose (A, B, C). qRT PCR of FGF23, Fetuin-A 
and TNFα in HepG2 after 24h from FGF23 overexpression (D, E, F). Asterisks 
indicate significant differences versus HepG2 (ctrl): *=p<0.01, **=p<0.01, 
***=p<0.001 by Student’s t-test. n=3/group. 
FGF23 and Fetuin-A interaction in the renal 
tubules 
Given this strict inter-relationship between 
FGF23 and Fetuin-A also in the circulation, we looked 
for a similar interaction also in the renal tissue, which 
is one of the main target sites of FGF23. Although a 
strong IS of both Fetuin-A (Fig 11A) and FGF23 (Fig 
11B) was observed, no co-localization of both 
molecules was detected (Fig 11C). 
Discussion  
In our recent articles [21, 22] we focused on 
FGF23 and Fetuin-A proteins that are involved in both 
bone and vascular system physiopathology, the first 
being a well-recognized bone-derived protein and the 
second being produced mainly by the liver. Our 
results demonstrated not only that Fetuin-A is 
produced also by bone cells and that its production is 
controlled by FGF23, but that both proteins are strictly 
linked to each other in the bone tissue. 
Then, we wondered: a) if these characteristics are 
present also in the liver, the main site of Fetuin-A 
production; b) if this was the case, which were the 
biochemical mechanism(s); c) if the strict interaction 
of FGF23 and Fetuin-A found in the bone is also 
present in the circulatory system. 
 
 
Figure 8. Semi-quantitative PCR of Fetuin-A promoter of HepG2 after 
FGF23/CHIP. Product size of human Fetuin-A promoter 146bp (A). Changes in 
Fetuin-A promoter expression after 24h from the addition of scalar FGF23 dose 
and after 24h from FGF23 overexpression (B). Asterisks indicate significant 
differences versus HepG2 (ctrl): **=p<0.01, ***=p<0.001 by Student’s t-test. 
n=3/group. 






Figure 9. Fetuin-A (A), FGF23 (B) and merge (C) IS in the periportal vein interstice (human liver). Cell co-localization of Fetuin-A and FGF23 detected by Duolink 
in situ experiment in the plasma of a CKD patient (D).  Scale Bars: 50μm. FGF23 WB in the FGF23/IP plasma samples of 3 CKD patients with high FGF23 levels (E P1I, 
P2III, P3V) and 2 CKD patients with low FGF23 levels (E P4, P5) and in the non-FGF23/IP plasma samples of the first three high FGF23 patients (E P1II, P2IV, P3VI). 
Fetuin-A WB in the FGF23/IP plasma samples of 3 CKD patients with high FGF23 levels (E P1VII, P2IX, P3XI, P4, P5) and 2 CKD patients with low FGF23 levels (E 
P4, P5) and in the non-FGF23/IP plasma samples of the first three high FGF23 patients (E P1VIII, P2X, P3XII). 
 
Starting from the experimental data obtained in 
the liver, in addition to the expected expression of 
Fetuin-A, we found also a strong FGF23 expression 
with a tight co-localization of the two proteins to each 
other in the liver tissue and in cultures of either 
primary hepatocytes and HepG2 cells. We chose to 
study also HepG2 since it is well known that human 
hepatocytes, though considered the most appropriate 
in vitro model to study human liver cells, often face a 
rapid functional loss combined with a poor 
proliferative speed [35], while HepG2 have a 
high proliferative rate and are easier to handle. 
Anyway, we proved the viability of our 
cultured primary hepatocytes showing a clear 
positivity for albumin IS.  
It is worth underlining that while all the 
detectable FGF23 was completely co-localized 
with Fetuin-A, the latter was also present as 
unbound protein. To further characterize the 
cytoplasmic site of FGF23/Fetuin-A co- 
localization, we looked for a possible 
interaction of this complex with an endosomal 
protein (Clathrin).  In fact, the IF appearance 
of the 3 immunostainings in HepG2 cells 
strongly suggests a co-localization of FGF23/ 
Fetuin-A complex in the endosomes. The 
physiopathological meaning of this co-local-
ization, if any, (intracellular trafficking, 
lysosome, secretory) deserves future studies. 
 To qualify the nature of FGF23 positivity 
in the liver, we looked for its expression by 
qRT-PCR. In fact, we found that both primary 
hepatocytes and HepG2 cells highly expressed 
not only Fetuin-A, but, though at a lesser 
 
 
Figure 10. IS of Fetuin (A), FGF23 (B) and merge (C) after cytospin centrifugation, IS of 
Fetuin (D), FGF23 (E) and merge (F) after plasma smear in human plasma. Scale bars: 50μm. 





extent, also FGF23 mRNA. It is also worth underlining 
that while Fetuin-A showed a higher expression in 
primary hepatocytes compared to HepG2; no 
difference was evident for FGF23 expression between 
the two diverse types of cells. The lack of any 
difference between the primary hepatocytes and the 
HepG2 cells is an important finding, since it is known 
that tumoral liver cells can non-physiologically 
express many FGFs (FGF8, FGF17, FGF18) [36, 37]. In 
any case, our results are confirmatory of previous 
studies, which have demonstrated that FGF23 is 
expressed also in the liver cells [23]. 
We also compared the entity of the FGF23 
expression in the liver cells with that of osteocytes 
(Positive Ctrl) and podocytes (Negative Ctrl) 
expression. In fact, we found that the amount of 
FGF23 expression in liver cells is almost in the 
midway between osteocytes and podocytes. This 
finding is confirmatory of a sizeable FGF23 expression 
in the liver, which was however consistently lower 
than that found in OS.  
To further explore the degree of closeness of 
FGF23 and Fetuin-A molecules observed in the IF 
studies in the liver, we investigated their 
co-localization by both WB and Duolink analyses.  
We found a strong FGF23 band presence in the 
FGF23/IP fraction while a complete absence in the 
non-FGF23/IP fraction, confirming the correctness of 
the procedure.  
We also found a clear Fetuin-A band in the 
FGF23/IP fraction, in both primary Hepatocytes and 
even more evidently in the HepG2. The presence of a 
small Fetuin-A band in non-FGF23/IP suggests the 
presence of an FGF23 unbound component in 
agreement with the findings obtained by IS. The 
paucity of this free component could be due to the 
dilution requested by the manufacturer’s instructions. 
The presence of a strict interaction between Fetuin-A 
and FGF23 was also suggested by the Duolink in situ 
results in HepG2 cells. Then, from the WB first results 
we may suppose that covalent disulfide bridge is one 
of the possible bonds between Fetuin-A and FGF23 
and that, while FGF23 is strictly linked to Fetuin-A, 
the last one could also circulate in an unbound 
manner. It is well known that all the members of the 
FGF family contain some cysteines protein which are 
involved in structural stability and that these 
cysteines are conserved as vestigial epitope though 
with an unclear role [38]. It has been suggested that 
cysteine residues could enhance the affinity of some 
FGFs (FGF1 and 2) for the FGF-binding protein 
(FGF-BP1), forming a disulfide bond between the 
carrier protein and these FGFs [39]. In the same way, 
it could be hypothesized that Fetuin-A might interact 
with the cysteine residues of FGF23 vestigial site. The 
high propensity to closely link between Fetuin-A due 
to its molecular properties with other factors is 
already known, so that it is difficult to obtain crude 
Fetuin-A with a purification process [9]. Furthermore, 
the capacity of Fetuin-A to link various growth factors 
creating “enigmatic properties” was already 
hypothesized [40]. However, further research is 
needed to better clarify the meaning of the strict link 
between Fetuin-A and FGF23. 
Subsequently, we evaluated if 
FGF23, in addition to being expressed, 
is also released by the liver cells. No 
relevant amount of FGF23 was present 
in the medium of both cell cultures, 
without significant difference between 
the two cell types. This finding could 
be explained by a fast degradation of 
the protein due to specific proteases 
(furin) as suggested by a recent study 
where transgenic mice, characterized 
by a conditional block of furin 
proteases in the liver tissue, could 
secrete FGF23 in the circulation [24]. 
We cannot exclude that the complete 
proteolysis of the intact FGF23, which 
very likely happens in the normal liver 
cells, is present also in the CKD liver 
cells: this point will deserve specific 
research in in vivo CKD experimental 
studies.  However, it is worth 
underlining that we dosed only the 
mature form of FGF23 (intact FGF23), 
 
 
Figure 11. IS of Fetuin (A), FGF23 (B) and merge (C) in human kidney tissue. Scale bars: 50μm. 





and it cannot be excluded that intact FGF23 might 
have been cleaved into C-terminal fragment(s). 
Since we previously found that the addition of 
FGF23 to the OS cultures resulted in consistent 
changes of FGF23 and Fetuin A expression [21], we 
aimed to explore if these findings were present in 
liver cells as well. After stimulating HepG2 with 
escalating FGF23 doses, we observed a clear, though 
not completely dose dependent, increase of FGF23 
expression, but only a slightly increased and biphasic 
expression of Fetuin-A, which was stimulated by the 
lowest and inhibited by the highest FGF23 doses. 
There is no counterintuitive explanation for this 
expression pattern in the liver cells. However, it has 
been recently demonstrated that the FGF23 
dependent stimulation of FGFR4, which is the only 
FGF receptor expressed in the liver, induces the 
release of inflammatory cytokines through a 
Klotho-independent pathway [26, 28, 32]. It is also 
well recognized that Fetuin-A, which plays also an 
anti-inflammatory role [41-45], can be either up- or 
down-regulated by other inflammatory cytokines [17, 
20]. Since it has been demonstrated that TNFα is an 
anti-inflammatory cytokine with inhibitory effects on 
Fetuin-A expression [42], we looked for the TNFα 
behavior after FGF23 stimulation. In fact, TNFα 
changes mirrored the FGF23 variations and at the 
highest TNFα mRNA levels corresponded to the 
lowest Fetuin-A expression. Therefore, we could 
hypothesize that a primary stimulatory effect of 
FGF23 on Fetuin-A expression might be dampened by 
the simultaneous increased levels of TNFα which has 
a predominant inhibitory effect. 
This hypothesis is indirectly confirmed by the 
results that we obtained after autocrine strong 
overexpression of FGF23 in hepatocytes. In fact, we 
found that FGF23 overexpression induced a striking 
up-regulation of TNFα expression associated with a 
deep downregulation of Fetuin-A expression.  
This finding might be of relevance, particularly 
in CKD patients, since the very high levels of FGF23 
often observed in this clinical setting could explain the 
contemporary increase in the inflammatory cytokines 
and the reduction of Fetuin-A levels [46, 47].  
First, we tried to clarify the biochemical 
mechanism(s) by which FGF23 stimulates Fetuin-A. 
To this end, after verifying that no known 
transcription factor (TF), common to FGF23 and 
Fetuin-A, has been as yet reported (Gene Cards® data 
base), we performed a CHIP of HepG2 with FGF23 
followed by a PCR amplification using the primers of 
human Fetuin-A promoter. In the nucleus, we 
observed that FGF23 affects nuclear transcription of 
the Fetuin-A promoter gene, possibly acting as a 
transcriptional factor. Our data cannot prove if FGF23 
acts alone or in cooperation with other TFs. 
Thereafter, we investigated if the Fetuin-A promoter 
activity was changed by the addition or 
overexpression of FGF23. In all these experimental 
conditions, the Fetuin-A promoter was significantly 
stimulated by FGF23. This finding is at variance with 
the biphasic effects of FGF23 on Fetuin-A protein 
levels (see above). At the present time, we could only 
hypothesize that this apparently discrepant effect on 
Fetuin-A promoter gene and Fetuin-A protein levels 
induced by progressively increasing levels of FGF23  
could be due to some unexplored epigenetic 
post-transcriptional regulation and/or to a 
counter-regulatory effect secondary played by 
inflammatory cytokines (TNFα/ NF-κB mechanism) 
which also are stimulated by FGF23[48, 49]. This 
intriguing question could be only answered by future 
studies. We know that CKD is characterized by high 
levels of FGF23 and a generalized inflammatory 
status. Both conditions have been put in relationship 
with the overwhelming incidence of cardio-vascular 
complications. We could hypothesize that, while 
relatively low-high levels of FGF23 could be 
protective for the CV system, given the stimulation of 
a “cardio-vascular” protective agent (Fetuin-A), the 
highest doses of FGF23 could act in a opposite 
direction, due to the contemporary stimulation of 
inflammatory cytokines which, in addition to their 
specific CV negative role, could also reverse the 
effects of FGF23 on Fetuin-A. 
To reinforce this information, we decided to add 
also information on IL6, another major inflammatory 
cytokine. In fact, IL6 behaves in a way almost 
overlapping to that of TNF alpha. 
Since in the present study and in our previous 
studies [21, 22] we found a strict co-localization of 
Fetuin-A and FGF23 molecules in the liver interstice 
of portal vein and in bone matrix, we wonder if this 
strict binding was present also in the circulatory 
system.  
In fact, we found a strict binding of these two 
proteins to each other in the blood of CKD patients, as 
highlighted by both FGF23/IP and Duolink in situ 
experiments. It is also worth noting that this strict 
interrelationship was evident at both high and low 
FGF23 levels. To avoid a possible artifact link due to 
the cytospin method, we compared the IF images of 
Fetuin-A and FGF23 co-localization obtained in the 
cytospin samples with plasma smears. Both 
experiments gave almost overlapping results, 
excluding potential technical factitious results. 
Overall, these results, reinforcing those observed 
in the tissue and cell cultures, strongly suggest a strict 
interrelationship between FGF23 and Fetuin-A. 
Then, to try to give an explanation to the 





meaning of the circulating complex FGF23-Fetuin-A, 
we examined whether this dimeric complex is present 
also at the sites where FGF23 displays its canonical 
effects, such as in the renal tubular cells. However, we 
were not able to find any co-localization of these 
proteins in renal tubules, excluding that the dimer 
could play a cooperative role in FGF23 renal activity. 
We did not explore other canonical and non-canonical 
sites of FGF23 activity, so we cannot exclude that at 
the other levels the FGF23-Fetuin-A dimer could play 
any effective role.  
Therefore, the meaning of this strict interaction 
remains largely to be clarified. We could just limit 
ourselves to hypothesize that Fetuin-A could play the 
role of carrier for FGF23, which in turn controls the 
production of the carrier itself. 
Conclusions 
In conclusion, our data show that FGF23 is 
expressed also in the liver, but, at variance with bone, 
it is not secreted, likely playing only autocrine and/or 
paracrine roles. The addition or overexpression of 
FGF23 in the liver cells have a biphasic effect on 
Fetuin-A production, with this behaviour potentially 
being explained by the contemporary stimulatory 
effect on inflammatory cytokines. We also found that 
FGF23 directly acts on the Fetuin-A promoter gene, 
possibly as a transcription factor. FGF23 and Fetuin-A 
are also present in the circulation, strictly bound to 
each other, while no co-localization is found in the 
kidney, which suggests a possible Fetuin-A role as a 
carrier protein for FGF23. Overall, we can hypothesize 
that the biphasic regulation of Fetuin-A production by 
FGF23 could add a piece in the puzzle of the intricate 
inter-relationships linking CKD to inflammation and 
possibly to CVD. 
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